Hilary Kramer

Hilary Kramer

Hilary Kramer is one of Wall Street’s most successful equity analysts and investment managers, with a reputation as a leading expert on today’s market movements, stock trends and economic outlook.

She received her MBA from the Wharton School at the University of Pennsylvania and her BA from Wellesley College with honors. Hilary Kramer got her start on Wall Street more than two decades ago at Lehman Brothers and Morgan Stanley where she was an analyst in the investment banking group covering natural resources, diversified industrials and energy companies. She was also the chief investment officer of a family office — overseeing a $5.2 billion global private equity and publicly-traded equity fund, and co-vice chairman of the $500 million Ibero-American Partners Fund (1997 to 2003).

In 2004, Hilary’s A&G Capital formed a specialized research arm and investment fund. The GreenTech 21st Century Master Fund focused on companies engaged in alternative energy, clean technologies, environmental infrastructure and services, agricultural and natural resources.

Today, Hilary Kramer is an in-demand commentator whose work often appears in investing publications such as the Wall Street Journal, New York Post, Bloomberg, Business Insider and Reuters and is a regular on CNBC, CNN and the Fox News Channel, providing stock market insight and economic observations.

Hilary Kramer is also the editor of several financial advisory services designed to help individual investors profit from her stock picking talents: Value Authority, GameChangers, Breakout Stocks, High Octane Trader, Absolute Capital Return, Inner Circle and Inner Circle Pro.

Recent Articles

Markets Trading in a Tight Range No Reason for Panic

Low U.S. interest rates are the new normal as are problems in Greece. The results are stalled markets with no direction.

Time to Take Profits at Cerner

Cerner has been in our portfolio for a fairly short time but has performed extremely well. Now is a good time to lock in profits.

A 3-Part Strategy for This Choppy Market

The market is choppy right now, with little positive forward momentum, so looking for a solid strategy is key. Here are three to get started.

VeriFone Stock Drops: What to Do Next

VeriFone shares have been slammed after disappointing earnings, but the business model has not changed.

3 Stocks to Help Weather the Financial Storm

After weathering the May storm and surviving Europe's turmoil, these three picks are inexpensive at this point.

Myriad Genetics Is a Biotech Buy

Myriad Technologies offers tests used to predetermine cancers and other diseases to provide pretreatment or prevention. Myriad is a biotech buy.

Genetic Testing a Chance to Profit From Prevention

Genetic testing and the sequencing of the gene is now 12 years old, and opportunities to profit through wise stock picks abound at this point.

Biotech’s Regeneron Is a New Game Changer Buy

Biotech's Regeneron is a strong buy based on its existing Eylea drug for macular degeneration, but the company also has a solid pipeline of products.

Down but Not Out: JPM Will Rebound

JPM’s stock is massively oversold, but it is no reflection on the health of the business. The company itself is strong and healthy -- in fact, it’s thriving.

The Market Sings the Song of Europe’s Woes

The situation in Europe, and in particular Greece and now Italy and Spain, threatens the stability and possible advance of U.S. markets. What comes next?